Table 3.

Clinical outcomes

Clinical GroupBaseline2 mo4 mo6 mo
Sertraline, N15988
 MADRS score24.5 (4.5)13.9 (5.8)10.6 (6.6)10.3 (5.8)
 Change from baseline−10.4 (−16.4 to −4.4)−14.1 (−19.6 to −8.6)−14.5 (−20.2 to −8.8)
Placebo, N15141313
  MADRS score25.3 (4.2)15.8 (4.8)11.1 (5.5)10.9 (5.1)
 Change from baseline−8.9 (−13.3 to −6.4)−14.8 (−18.1 to −11.4)−14.9 (−18.4 to −11.5)
Between-group difference−1.9 (−6.5 to 2.7)−0.45 (−6.0 to 5.1)−0.67 (−5.7 to 4.4)
  • Mean (SD) values for the Montgomery–Asberg Depression Rating Scale (MADRS) score at 2, 4, and 6 months for the sertraline and placebo groups. The treatment effect is estimated as the difference between the observed outcome scores (95% confidence intervals) for the sertraline and placebo groups. Because the difference between the groups was effectively zero at 6 months, no adjusted differences have been estimated. The changes in the MADRS score from baseline to 2, 4, and 6 months (95% confidence intervals) are also shown. —, not applicable.